Table 3:

Baseline clinical and laboratory characteristics for patients with primary myelofibrosis with and without pulmonary hypertension

	PMF without PH n=8 (50%)	PMF with Group 5 PH n=8 (50%)	P-value
Age	65	74	0.07
Sex
Male	6	2	0.13
Female	2	6
WBC	3.7	4.6	0.38
Hgb	10.4	9.0	0.95
Platelets	97	261	0.56
Constitutional Symptomsa	2(29)% (n=7)	0 (n=8)	0.2
Transfusion Requirement	3	3	1.0
Circulating Blast Cells ≥1%a	2(29%) (n=7)	2(25%) (n=8)	1.0
JAK 2 Positiveb	2(40)% (n=5)	1(17%) (n=6)	0.55
Median DIPSS Risk	2	2.5	0.37

^a-Sample size (n) limited by incomplete data entry in the electronic medical record

^b-Sample size limited based on availability of ordered test and/or results